



IN THE CLAIMS

Amended Claims


1. (Currently Amended) A compound of the formula (Ia), (Ib) or (Ic),




(Ia)



(Ib)



(Ic)



in which

A



R^1 is hydrogen, C_1 - C_{20} -alkyl, C_2 - C_{20} -alkenyl, C_2 - C_{20} -alkynyl, cycloalkyl with three to eight ring carbon atoms, cycloalkenyl with three to eight ring carbon atoms, cycloalkylalkyl with five to six ring carbon atoms, aryl, heteroaryl, alkylaryl, alkylheteroaryl, arylalkyl, heteroarylalkyl, wherein R^1 is unsubstituted or substituted with at least one substituent chosen from R^6 ,

R^2 is C_1 - C_{20} -alkyl, C_2 - C_{20} -alkenyl, C_2 - C_{20} -alkynyl, cycloalkyl with three to eight ring carbon atoms, cycloalkenyl with three to eight ring carbon atoms, cycloalkylalkyl with five to six ring carbon atoms, aryl, heteroaryl, alkylaryl, alkylheteroaryl, arylalkyl, or heteroarylalkyl wherein R^2 is unsubstituted or substituted with at least one substituent chosen from R^6 ,

$R^{2'}$ is C_2 - C_{20} -alkenyl, C_2 - C_{20} -alkynyl, cycloalkenyl with three to eight ring carbon atoms, cycloalkylalkyl with five to six ring carbon atoms, aryl, heteroaryl, alkylaryl, alkylheteroaryl, arylalkyl, or heteroarylalkyl wherein $R^{2'}$ is unsubstituted or substituted with at least one substituent chosen from R^6 .

or R^1 and R^2 , together with the nitrogen atom bearing them, form a 3-8-membered ring which may optionally comprises 0, 1 or 2 further heteroatoms chosen from N, O, and S, and wherein said 3-8-membered ring is unsubstituted or substituted by at least one substituent chosen from R^6 ,

R^3 is hydrogen, -CO-alkyl, -CO-alkylaryl, -CO-alkylheteroaryl, -CO-aryl, or -CO-heteroaryl,

R⁴ is C₁-C₂₀-alkyl, C₂-C₂₀-alkenyl, C₂-C₂₀-alkynyl, cycloalkyl with three to eight ring carbon atoms, cycloalkenyl with three to eight ring carbon atoms, cycloalkylalkyl with five to six ring carbon atoms, aryl, heteroaryl, alkylaryl, alkylheteroaryl, arylalkyl, heteroarylalkyl, -CO-O-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -CO-alkyl, -CO-aryl or -CO-heteroaryl wherein R⁴ is unsubstituted or substituted with at least one substituent chosen from R⁷,

R^{4'} is C₂-C₂₀-alkenyl, C₂-C₂₀-alkynyl, cycloalkyl with three to eight ring carbon atoms, cycloalkenyl with three to eight ring carbon atoms, cycloalkylalkyl with five to six ring carbon atoms, heteroaryl, alkylheteroaryl, heteroarylalkyl, -CO-O-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -CO-O-aryl or -CO-O-heteroaryl wherein R^{4'} is unsubstituted or substituted with at least one substituent chosen from R⁷.

R⁵ is hydrogen, -CO-alkyl, -CO-alkylaryl, -CO-alkylheteroaryl, -CO-aryl, or CO-heteroaryl,

R⁶ is -F, -OH, -O-(C₁-C₁₀)-alkyl, -O-phenyl, -O-CO-(C₁-C₁₀)-alkyl, -O-CO-aryl, -O-CO-heteroaryl, -NR⁸R⁹, oxo, phenyl, -CO-(C₁-C₅)-alkyl, -CF₃, -CN, -CONR⁸R⁹, -COOH, -CO-O-(C₁-C₅)-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -S(O)_n-(C₁-C₅)-alkyl, -SO₂-NR⁸R⁹,

R⁷ is -F, -OH, -O-(C₁-C₁₀)-alkyl, -O-phenyl, -O-CO-(C₁-C₁₀)-alkyl, O-CO-O-aryl, O-CO-O-heteroaryl, -NR⁸R⁹, oxo, phenyl, -CO-(C₁-C₅)-alkyl, -CF₃, -CN, -CONR⁸R⁹, -COOH, -CO-O-(C₁-C₅)-alkyl, -CO-O-aryl, -S(O)_n-(C₁-C₅)-alkyl, -SO₂-NR⁸R⁹,

R⁸ is hydrogen or C₁-C₂₀-alkyl, and

R⁹ is hydrogen, C₁-C₂₀-alkyl, aryl, or heteroaryl,

wherein aryl groups are carbocyclic aryl groups,

wherein heteroaryl groups are 5- to 7-membered unsaturated heterocycles comprising 1-4 heteroatoms chosen from O, N, and S,

or a physiologically acceptable salt, hydrate, or ester thereof, in any stereoisomeric or tautomeric form.

2. (Currently Amended) The compound of the formula (Ia) as claimed in claim 1, in which

R¹ is hydrogen, (C₁-C₁₀)-alkyl, (C₃-C₈)-cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, (C₁-C₃)-alkylaryl, (C₁-C₃)-alkylheteroaryl, arylalkyl, or heteroarylalkyl, wherein R¹ is unsubstituted or the alkyl radicals are substituted with at least one substituent chosen from R⁶,

R² is (C₁-C₁₀)-alkyl, (C₃-C₈)-cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, (C₁-C₃)-alkylaryl, or (C₁-C₃)-alkylheteroaryl wherein R² is unsubstituted or the alkyl radicals are substituted with at least one substituent chosen from R⁶,

or R¹ and R² may, together with the nitrogen atom bearing them, form a 3-8-membered ring, wherein said 3-8-membered ring optionally comprises 0, 1 or 2 further heteroatoms chosen from N, O, and S and wherein said 3-8-membered ring is unsubstituted or substituted by at least one substituent chosen from R⁶,

R³ is hydrogen, -CO-(C₁-C₇)-alkyl, -CO-(C₁-C₃)-alkylaryl, -CO-(C₁-C₃)-alkylheteroaryl, -CO-aryl, or -CO-heteroaryl,

R⁴ is (C₁-C₁₀)-alkyl, aryl, heteroaryl, (C₁-C₃)-alkylaryl, (C₁-C₃)-alkylheteroaryl, -CO-O-(C₁-C₅)-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -CO-(C₁-C₅)-alkyl, -CO-aryl or -CO-heteroaryl, wherein R⁴ is unsubstituted or the alkyl radicals are substituted with at least one substituent chosen from R⁷,

R^5 is hydrogen, CO-(C₁-C₇)-alkyl, -CO-(C₁-C₃)-alkylaryl, -CO-(C₁-C₃)-alkylheteroaryl, -CO-aryl, or -CO-heteroaryl,

R^6 is -F, -OH, -O-(C₁-C₁₀)-alkyl, -O-phenyl, -O-CO-(C₁-C₁₀)-alkyl, -O-CO-aryl, -O-CO-heteroaryl, -NR⁸R⁹, oxo, phenyl, -CO-(C₁-C₅)-alkyl, -CF₃, -CN, -CONR⁸R⁹, -COOH, -CO-O-(C₁-C₅)-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -S(O)_n-(C₁-C₅)-alkyl, -SO₂-NR⁸R⁹,

R^7 is -F, -OH, -O-(C₁-C₁₀)-alkyl, -O-phenyl, -O-CO-(C₁-C₁₀)-alkyl, -O-CO-aryl, -O-CO-heteroaryl, -NR⁸R⁹, oxo, phenyl, -CO-(C₁-C₅)-alkyl, -CF₃, -CN, -CONR⁸R⁹, -COOH, -CO-O-(C₁-C₅)-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -S(O)_n-(C₁-C₅)-alkyl, -SO₂-NR⁸R⁹,

R^8 is hydrogen or (C₁-C₅)-alkyl, and

R^9 is hydrogen, (C₁-C₅)-alkyl or phenyl,

wherein each aryl group is phenyl or naphthyl, and

wherein said heteroaryl groups are 5- to 7-membered unsaturated heterocycles comprising 1-4 heteroatoms chosen from O, N, and S,

wherein said phenyl, naphthyl and heteroaryl groups are substituted groups which are substituted by at least one substituent chosen from halogen, (C₁-C₅)-alkyl or phenyl, -OH, -O-(C₁-C₅)-alkyl, (C₁-C₂)-alkylenedioxy, -N⁸R⁹, -NO₂, -CO-(C₁-C₅)-alkyl, -CF₃, -CN, -CONR⁸R⁹, -COOH, -CO-O-(C₁-C₅)-alkyl, -S(O)_n-(C₁-C₅)-alkyl, -SO₂-NR⁸R⁹,

wherein n is 0, 1 or 2,

or a physiologically acceptable salt, hydrate, or ester thereof, in any stereoisomeric or tautomeric form.

3. (Currently Amended) A compound of the formula (Ia) as claimed in claim 1, in which

R¹ is hydrogen, unsubstituted (C₂-C₄)-alkyl, substituted (C₂-C₄)-alkyl which is substituted by at least one R⁶, or (C₁-C₂)-alkyl aryl or (C₁-C₂)-alkylheteroaryl,

R² is unsubstituted (C₂-C₄)-alkyl, substituted (C₂-C₄)-alkyl which is substituted by at least one R⁶, or cyclohexylmethyl or (C₁-C₂)-alkylaryl or (C₁-C₂)-alkylheteroaryl,

or R¹ and R², together with the nitrogen atom bearing them, form a 5-7-membered ring wherein said 5-7-membered ring optionally comprises an additional heteroatom chosen from N, O, and S,

R³ is hydrogen, -CO-(C₁-C₃)-alkyl, -CO-aryl or -CO-heteroaryl,

R⁴ is aryl, heteroaryl, (C₁-C₅)-alkyl, -CO-O-aryl or -CO-heteroaryl, wherein R⁴ is unsubstituted or substituted with at least one substituent chosen from R⁷,

R⁵ is hydrogen,

R⁶ is -OH, -O-(C₁-C₃)-alkyl, -NR⁸R⁹ or -COOH, and

R⁷ is -OH, (C₁-C₁₀)-alkyloxy, phenoxy or oxo,

wherein each aryl group is phenyl,

wherein said heteroaryl groups are chosen from thiophenyl, furyl and pyridyl,

wherein said phenyl, thiophenyl, furyl or pyridyl groups are unsubstituted groups or substituted groups which are substituted by at least one substituent chosen from (C₁-C₃)-alkyl, halogen, (C₁-C₃)-alkyloxy and (C₁-C₂)-alkylenedioxy, and

or a physiologically acceptable salt, hydrate, or ester thereof, in any stereoisomeric or tautomeric form.

4. (Currently Amended) A compound of the formula (Ia) as claimed in claim 1, in which

R¹ is arylmethyl,

R² is arylmethyl or cyclohexylmethyl,

or R¹ and R², together with the nitrogen atom bearing them, form a pyrrolidine, piperidine, morpholine, dimethylmorpholine, thiomorpholine, or N-(C₁-C₂)-alkylpiperazine ring,

R³ is hydrogen,

R⁴ is alkyl or 1,2-dihydroxypropyl,

R⁵ is hydrogen,

R⁶ is -OH, -O-(C₁-C₃)-alkyl, -NR⁸R⁹ or -COOH, and

R⁷ is -OH, decyloxy or phenoxy,

wherein each aryl group is chosen from unsubstituted phenyl or substituted phenyl, which is substituted by at least one substituent chosen from (C₁-C₃)-alkyl, halogen and (C₁-C₃)-alkyloxy and (C₁-C₂)-alkylenedioxy,

or a physiologically acceptable salt, hydrate, or ester thereof, in any stereoisomeric or tautomeric form.

5. (Currently Amended) The compound of formula (Ia) as claimed in claim 1, which is a tetrahydropteridine wherein R^4 is aryl, heteroaryl, (C_1-C_5) -alkyl -CO-O-aryl or -CO-O-(heteroaryl), and wherein said R^4 is unsubstituted or substituted with at least one substituent chosen from R^7 .

6. (Currently Amended) The compound of formula (Ia) as claimed in claim 1, ~~which is a~~ pteridine wherein

R^1 and R^2 are each, independently alkyl aryl, or heteroaryl, or

R^1 is hydrogen and R^2 is cycloalkyl or cycloalkylalkyl, and

wherein R^4 is aryl, (C_1-C_5) -alkyl -CO-O-aryl or -CO-O-(heteroaryl), wherein said R^4 is unsubstituted or substituted with at least one substituent chosen from R^7 .


7. (Currently Amended) A pharmaceutical comprising a compound of formula (Ia), (Ib), or (Ic) as claimed in claim 1 and an additional ingredient chosen from conventional excipients and additives.

8. (Previously Amended) A method of treating or preventing strokes comprising administration of at least one pharmaceutical of claim 7 to a patient in need thereof.

9. (Cancelled)

10. (Cancelled)


11. (Currently Amended) A process for preparing ~~the a~~ a compound of formula (Ia), (Ib), or (Ic) as claimed in claim 1 comprising reacting a compound of the formula II




with a compound of the formula III




which results in a compound of the formula IV



wherein the compound of formula IV is converted to a compound of formula V by catalytic hydrogenation



and wherein a compound of formula V is reacted with a compound of the formula VI



(VI)

to give a compound of formula (Ia), (Ib), or (Ic).

12 - 14. (Cancelled).